A Trial to Evaluate DR-2021 in Women With Secondary Amenorrhea
This study has been completed.
Sponsor:
Duramed Research
Information provided by:
Duramed Research
ClinicalTrials.gov Identifier:
NCT00196391
First received: September 13, 2005
Last updated: January 8, 2010
Last verified: January 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Detailed Description:
This is a multicenter trial to compare the effectiveness of 4 doses of DR-2021 with placebo and oral micronized progesterone in inducing withdrawal bleeding in women with secondary amenorrhea.
Condition | Intervention | Phase |
---|---|---|
Amenorrhea |
Drug: DR-2021a Drug: DR-2021b Drug: DR-2021c Drug: DR-2021d Drug: DR-2021e Other: Placebo |
Phase 2 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
Official Title: | A Multicenter Study to Evaluate Induction of Withdrawal Bleeding After Administration of DR-2021 in Women With Secondary Amenorrhea |
Resource links provided by NLM:
Further study details as provided by Duramed Research:
Primary Outcome Measures:
- Proportion of patients who have received 10 days of treatment and reported withdrawal bleeding. [ Time Frame: Throughout study period ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Time to onset, duration, and severity of withdrawal bleeding. [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
Estimated Enrollment: | 180 |
Study Start Date: | September 2005 |
Study Completion Date: | April 2007 |
Primary Completion Date: | April 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Experimental: 1 |
Drug: DR-2021a
1 capsule daily for 10 days
Other Name: Micronized progesterone
|
Experimental: 2 |
Drug: DR-2021b
1 capsule daily for 10 days
Other Name: Micronized Progesterone
|
Experimental: 3 |
Drug: DR-2021c
1 capsule daily for 10 days
Other Name: Micronized Progesterone
|
Experimental: 4 |
Drug: DR-2021d
1 capsule daily for 10 days
Other Name: Micronized Progesterone
|
Experimental: 5 |
Drug: DR-2021e
1 capsule daily for 10 days
|
Placebo Comparator: 6 |
Other: Placebo
1 matching placebo capsule for 10 days
|
Detailed Description:
In this multicenter trial patients will be randomized to receive DR-2021, oral micronized progesterone, and placebo to evaluate the effects on withdrawal bleeding in women with secondary amenorrhea. Patients will be treated for 10 days and study participation will be approximately 24 days. Patients will undergo a physical exam including a pelvic and breast exam. Patients will be required to complete bleeding and spotting information daily in a diary.
Eligibility
Ages Eligible for Study: | 18 Years to 50 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Not pregnant
- Secondary amenorrhea or oligomenorrhea of at least 50 days duration
- Not currently on any hormonal medication
- Not at risk of pregnancy or willing to use a non-hormonal method of birth control during the study (ie, condom)
Exclusion Criteria:
- Use an injectable or implantable estrogens, progestins, or androgens within the last 6 months
- Use of any hormonal birth control within the last 3 months
- Any contraindication to the use of progestins
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00196391
Show 27 Study Locations
Show 27 Study Locations
Sponsors and Collaborators
Duramed Research
Investigators
Study Chair: | Duramed Protocol Chair | Duramed Research, Inc. |
More Information
Additional Information:
No publications provided
Keywords provided by Duramed Research:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 16, 2012
Additional Information:
No publications provided
Responsible Party: | Duramed Protocol Chair, Duramed Research, Inc. |
ClinicalTrials.gov Identifier: | NCT00196391 History of Changes |
Other Study ID Numbers: | DR-MPG-201 |
Study First Received: | September 13, 2005 |
Last Updated: | January 8, 2010 |
Health Authority: | United States: Food and Drug Administration |
Keywords provided by Duramed Research:
secondary amenorrhea progesterone |
Additional relevant MeSH terms:
Amenorrhea Menstruation Disturbances Pathologic Processes Progesterone Progestins |
Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on October 16, 2012